Facebook Twitter LinkedIn Google Plus RSS

NeoStem subsidiary announces agreement with Sentien Biotechnologies

By ,

NeoStem Inc., of Allendale, and its subsidiary, Progenitor Cell Therapy LLC, announced today the execution of a services agreement with Sentien
Biotechnologies Inc.

According to an announcement, under the agreement, PCT will provide services to support Sentien's development of its cell therapy product, including technology transfer, training and manufacturing. Terms were not disclosed.

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!